Capital International Investors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-47,027
| Closed | -$4.41M | – | 452 |
|
|
2022
Q1 | $4.41M | Sell |
47,027
-10,550
| -18% | -$989K | ﹤0.01% | 434 |
|
|
2021
Q4 | $4.9M | Sell |
57,577
-389,442
| -87% | -$33.2M | ﹤0.01% | 437 |
|
|
2021
Q3 | $42.9M | Sell |
447,019
-669,144
| -60% | -$64.2M | 0.01% | 360 |
|
|
2021
Q2 | $109M | Sell |
1,116,163
-456,163
| -29% | -$44.4M | 0.02% | 293 |
|
|
2021
Q1 | $153M | Sell |
1,572,326
-1,840,323
| -54% | -$179M | 0.04% | 249 |
|
|
2020
Q4 | $327M | Sell |
3,412,649
-862,827
| -20% | -$82.7M | 0.09% | 194 |
|
|
2020
Q3 | $411M | Sell |
4,275,476
-1,820,920
| -30% | -$175M | 0.13% | 153 |
|
|
2020
Q2 | $744M | Buy |
6,096,396
+76,293
| +1% | +$9.31M | 0.24% | 109 |
|
|
2020
Q1 | $521M | Buy |
6,020,103
+187,960
| +3% | +$16.3M | 0.21% | 112 |
|
|
2019
Q4 | $627M | Buy |
5,832,143
+1,667
| +0% | +$179K | 0.21% | 118 |
|
|
2019
Q3 | $525M | Buy |
5,830,476
+200,122
| +4% | +$18M | 0.2% | 117 |
|
|
2019
Q2 | $475M | Buy |
5,630,354
+1,203,754
| +27% | +$102M | 0.19% | 123 |
|
|
2019
Q1 | $390M | Buy |
4,426,600
+901,600
| +26% | +$79.4M | 0.17% | 137 |
|
|
2018
Q4 | $252M | Buy |
3,525,000
+3,267,000
| +1,266% | +$233M | 0.13% | 157 |
|
|
2018
Q3 | $31.7M | Buy |
+258,000
| New | +$31.7M | 0.01% | 304 |
|